6 Best Peptides for Visceral Fat

What to Know Before Choosing a Peptide for Visceral Fat

Visceral fat is not the fat you can pinch. It sits deeper, packed around the liver, pancreas, and intestines, and it behaves differently from subcutaneous fat at a biological level. It is more metabolically active, more tightly linked to insulin resistance and cardiovascular risk, and it carries a higher density of growth hormone receptors than subcutaneous fat. That last point is why certain peptides can selectively shrink the deep abdominal depot while leaving surface fat largely alone.

The peptides people reach for when tackling visceral fat fall into two broad camps. One camp works through the growth hormone axis, stimulating the body's own GH signaling to drive selective visceral fat breakdown. The other works through appetite and metabolic pathways, producing substantial total fat loss that includes visceral fat as part of a broader reduction. Understanding which camp a compound belongs to matters because the goals are different: one targets deep fat selectively, the other reduces everything together.

Every compound in this guide earned its place because people use it or are actively discussing using it for visceral fat reduction. That is the only filter applied here. FDA-approved, telemedicine-prescribed, and research-only compounds are all included. Some have Phase 3 randomized controlled trial data. Others have animal studies, limited human data, or primarily community-reported experience from user protocols. The evidence for each is described honestly inside its entry, not used as a reason to omit it from the list.

The entries are numbered, and that ordering reflects how prominently each compound appears in research and documented real-world use for this goal, not a recommendation that one is better than another for you. The compound that fits your situation depends on factors an article cannot assess. That is exactly what the app is built to evaluate.

1. Tesamorelin: The Only FDA-Approved Option for Visceral Fat

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the signal the hypothalamus sends to the pituitary gland to trigger a pulse of growth hormone. When tesamorelin binds to GHRH receptors on the pituitary, it stimulates GH release in a pulsatile, physiologically natural pattern rather than flooding the system the way injected GH does. That GH pulse then drives the liver to produce IGF-1, insulin-like growth factor 1, which promotes the breakdown of stored triglycerides in a process called lipolysis. Visceral fat turns out to be disproportionately responsive to this signal because of its higher density of GH receptors compared to the fat just under the skin.

The result is selective reduction of deep abdominal fat without meaningful loss of subcutaneous fat, and that selectivity is confirmed not by subjective impressions but by CT scans measuring visceral adipose tissue area at the L4 to L5 vertebral level, which is the clinical gold standard for this measurement.

The trial data here is the most rigorous in the field. Multiple double-blind, placebo-controlled Phase 3 trials showed visceral fat reductions of 15 to 18 percent over 26 weeks, with an absolute reduction of roughly 34 square centimeters of visceral adipose tissue area while the placebo group actually gained visceral fat over the same period. Liver fat fell by around 37 percent in the subset of participants with HIV-associated fatty liver disease. Measurable reduction was detectable by week 13. Subcutaneous fat showed minimal change, confirming the selective effect directly.

Those trials were conducted primarily in people with HIV-associated lipodystrophy, a condition where antiretroviral therapy drives abnormal visceral fat accumulation. That is the FDA-approved indication: tesamorelin carries approval specifically for HIV-associated visceral adiposity, sold under the brand name EGRIFTA SV. Off-label use in non-HIV patients with excess visceral fat happens under qualified physician supervision, but that use is not FDA-approved, and the trial population does not directly represent a general metabolically obese group. The reduction also reverses when the compound is stopped, so ongoing administration is required to maintain results.

Community users who run tesamorelin protocols report a tighter midsection and reduced waist circumference over months of consistent use, and consistently frame this as a multi-month commitment rather than a short-cycle intervention. The major randomized controlled trials found no statistically significant difference in overall adverse events between the treatment and placebo groups, though injection site reactions, fluid retention, and joint discomfort are commonly noted. Glucose and insulin should be monitored throughout a course because the compound can affect insulin sensitivity.

For anyone whose primary goal is selective reduction of deep abdominal fat, tesamorelin is the most evidence-supported starting point in this field by a meaningful margin.

2. Tirzepatide: For Substantial Total Body Fat Loss Including Visceral

Tirzepatide is a dual agonist at two incretin receptors: GLP-1 and GIP, meaning it activates both the glucagon-like peptide-1 pathway and the glucose-dependent insulinotropic polypeptide pathway at the same time. GLP-1 receptor activation reduces appetite and slows gastric emptying, making it easier to eat less. GIP activation appears to enhance the GLP-1 effect and may improve how the body handles fat storage and energy use. Together the dual mechanism produces total body fat loss that consistently exceeds what GLP-1 agonists achieve alone in head-to-head studies.

Tirzepatide is FDA-approved for obesity and type 2 diabetes and carries strong Phase 3 randomized controlled trial data supporting significant reductions in total body weight. Visceral fat falls as part of that overall reduction. What tirzepatide does not do is selectively target visceral fat the way tesamorelin does: subcutaneous fat decreases alongside visceral fat, and the mechanism is appetite and metabolic regulation rather than direct engagement of the GH axis. For someone whose goal is losing a substantial amount of weight with visceral fat reduction as a component of that picture, tirzepatide has the strongest evidence base among the non-GH-axis options.

It is prescribed via licensed physicians and telemedicine platforms under its approved indications and widely available through standard prescription channels. GLP-1 class compounds carry class-level contraindications including personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, and the characteristic GI side effects including nausea, diarrhea, and constipation are common, particularly during dose escalation.

3. Semaglutide: The Most Accessible GLP-1 Option

Semaglutide is a GLP-1 receptor agonist, activating the same glucagon-like peptide-1 pathway that forms one half of tirzepatide's mechanism. It reduces appetite, slows gastric emptying, and produces clinically meaningful weight loss with a well-established published evidence base. It is FDA-approved for obesity under the brand name Wegovy and for type 2 diabetes as Ozempic, and it is currently the most widely available of the prescription compounds in this space, with broad telemedicine access and a mature prescription pathway across the United States.

Published randomized controlled trials show significant total body weight loss with semaglutide, and visceral fat decreases as part of that overall reduction. Like tirzepatide, semaglutide reduces the whole fat picture rather than targeting the deep abdominal depot specifically: it is not selective for visceral fat. For people whose primary driver is total weight reduction with visceral fat improvement as a downstream effect, semaglutide has a well-established evidence base and is the most straightforward to access through standard medical channels.

Side effects follow the GLP-1 class profile: nausea, diarrhea, constipation, and reduced appetite are common, particularly as dosing escalates. The same class-level thyroid cancer history contraindication that applies to tirzepatide applies to semaglutide as well.

4. Retatrutide: The Emerging Triple Agonist

Retatrutide adds a third receptor to the dual-agonist framework of tirzepatide. It activates GLP-1, GIP, and glucagon receptors simultaneously, making it a triple agonist developed by Eli Lilly. The glucagon receptor component is the key differentiator from tirzepatide. Glucagon agonism increases energy expenditure and promotes the breakdown of fat stored in the liver, effects that the GLP-1 and GIP pathways do not produce on their own. In early clinical data, that third mechanism appears to push total fat loss beyond what dual agonism achieves, and the glucagon component may contribute to enhanced reduction of liver fat and visceral fat specifically.

Phase 2 trial data shows total weight loss that exceeds results seen with semaglutide and tirzepatide in early comparative analyses, and preliminary findings point toward enhanced hepatic and visceral fat reduction compared to dual agonists. That finding is preliminary. The trial data is not yet as robustly established as the Phase 3 evidence behind tesamorelin or the FDA-approved GLP-1 agents, and retatrutide remains investigational as of 2026, unavailable as a standard prescription medication.

Side effects are expected to follow the GLP-1 class pattern, with potential additional effects from glucagon agonism, though the complete long-term safety picture is still accumulating as trials progress. For people tracking the emerging field of fat-loss peptides, retatrutide is one of the most closely watched compounds, and its glucagon component makes it particularly relevant to the visceral fat conversation even at this early stage.

5. AOD-9604: For Fat Breakdown Without Systemic GH Axis Effects

AOD-9604 is a synthetic fragment of human growth hormone, specifically the segment spanning amino acids 176 to 191 at the C-terminal end of the full hGH molecule. The design rationale behind it was that the fat-metabolizing properties of growth hormone appeared to be localized to one region of the molecule, separate from its anabolic and blood-sugar-altering properties. AOD-9604 was engineered to isolate that lipolytic signal: it promotes the breakdown of fat cells and inhibits the formation of new fat cells, a process called lipogenesis, without triggering the growth effects or insulin-disrupting properties of full growth hormone.

That mechanism positions it as an option for people interested in fat breakdown who want to avoid the systemic GH axis effects that come with compounds like tesamorelin or CJC-1295. It appears regularly in community protocols and functional medicine settings, often stacked alongside tesamorelin or other GH-axis peptides to layer a more direct lipolytic signal on top of pituitary-level stimulation.

AOD-9604 is not FDA-approved for any indication. No Phase 3 randomized controlled trial data exists specifically examining visceral fat reduction. The human evidence base is limited, and the bulk of what circulates about its use comes from community-reported experience in user protocols and off-label use in concierge medicine contexts. Animal studies and early investigational work support the lipolytic mechanism, but direct translation to selective visceral fat loss in humans has not been established with the same rigor as tesamorelin's trial record. It is available primarily as a research compound, and the sourcing and purity concerns that apply to unregulated research chemicals generally apply here.

For people already running a tesamorelin protocol or exploring body recomposition options, AOD-9604 comes up consistently in community discussion as a stacking addition. The evidence here is experiential rather than clinical, and anyone considering it should weigh that gap carefully.

6. MOTS-c: The Mitochondrial Metabolism Approach

MOTS-c occupies a genuinely different category from everything else on this list. It is a mitochondrial-derived peptide, meaning it is encoded not by nuclear DNA but by mitochondrial DNA, specifically a region of the 12S ribosomal RNA gene. The body produces it naturally, and it functions as a metabolic signal that activates AMPK, which stands for AMP-activated protein kinase. AMPK is sometimes described as the cell's energy sensor: a molecular switch that, when activated, shifts cells away from fat storage and toward fat oxidation and more efficient fuel use. MOTS-c activates that switch through a mechanism entirely distinct from the GH axis and the incretin pathways that drive all the other compounds in this guide.

In animal models, MOTS-c has shown reductions in visceral fat and liver fat accumulation, improvements in insulin sensitivity, and preserved metabolic function even on high-fat diets. Those findings are mechanistically coherent and genuinely interesting. The limitation is that the human evidence base is thin. No robust published human clinical trial data establishes visceral fat reduction from exogenous MOTS-c in people as of 2026. What exists beyond the animal models is user-reported experience from community protocols and investigational use in functional medicine, where it is sometimes added alongside other fat-loss peptides as a mitochondrial support layer given its distinct AMPK mechanism.

MOTS-c is not FDA-approved for any indication and is available as a research compound, carrying the same sourcing and purity uncertainties that apply to other unregulated peptides. Its endogenous origin is sometimes cited as a favorable sign for tolerability, since the body makes it naturally, but that does not guarantee the safety of exogenous administration at research-protocol levels, and the long-term human safety picture has not been established.

MOTS-c is the most niche compound on this list for visceral fat specifically, but it belongs here because it is genuinely part of the active conversation among people working on metabolic health and deep abdominal fat, and its AMPK mechanism offers something no other compound in this space provides.

How These Peptides Compare

Frequently Asked Questions

Is tesamorelin the only peptide proven to selectively reduce visceral fat?

Among all the peptides currently discussed for this goal, tesamorelin is the only one with Phase 3 randomized controlled trial data showing selective reduction of visceral fat without corresponding loss of subcutaneous fat, confirmed by CT scan measurement. The GLP-1 class compounds reduce visceral fat as part of broad total body fat loss, not as a selective effect on the deep abdominal depot. No other peptide has matched tesamorelin's evidentiary standard for targeted visceral fat reduction in humans.

Are these peptides legal to obtain without a prescription?

Tesamorelin, tirzepatide, and semaglutide are prescription medications requiring a licensed physician or telemedicine provider. Retatrutide is investigational and not available outside clinical trials as a standard prescription. AOD-9604 and MOTS-c are sold in some markets as research chemicals, a classification that means they are not FDA-approved for human use and are not subject to the manufacturing and purity oversight that applies to pharmaceutical products. Obtaining and using research chemicals for personal use carries sourcing and quality risks that prescription compounds do not.

Do any of these peptides work without changing diet or exercise habits?

The clinical trial data for tesamorelin was generated in controlled settings, and community users consistently report stronger results when proper nutrition accompanies the protocol. The GLP-1 class compounds suppress appetite, which tends to reduce caloric intake as a downstream effect, but the underlying physiology is still supported by and responsive to how a person eats and moves. No compound in this list has been shown to produce robust visceral fat reduction in the complete absence of lifestyle factors, and all of them work with the body's metabolic systems rather than independently of them.

How long does it typically take to see results?

The clinical timeline varies by compound. Tesamorelin's Phase 3 trials showed measurable visceral fat reduction appearing at week 13, with full effects assessed at 26 weeks. Community users often report noticing a difference in waist circumference or midsection firmness around the two-month mark, with the effect continuing to build over subsequent months. GLP-1 class compounds tend to produce visible weight changes earlier due to appetite suppression, but visceral fat reduction as a specific outcome takes longer to measure and verify. For all of these compounds, meaningful and measurable change should be expected over months rather than weeks.

Can these peptides be combined with each other?

Combining peptides for visceral fat is common in functional medicine and concierge medicine practice. Tesamorelin is frequently used alongside GLP-1 agents for people who want both selective visceral fat reduction and broader weight management, and it is also paired with AOD-9604 in some protocols for layered lipolytic effects. MOTS-c is sometimes added as a mitochondrial support compound given its distinct AMPK mechanism. These combinations are off-label and require medical supervision, and their interaction profiles have not been established through controlled trials the way individual compounds have. Anyone considering a stacked approach should work with a qualified clinician.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for visceral fat in one place.